Dopamine agonists and valvular heart disease in patients with Parkinson's disease: Evidence and mystery

Journal of Neurology

Volumn 254, Issue SUPPL. 5, 2007, Pages 74-78

  Yamamoto, Mitsutoshi ^a   Uesugi, Tadahisa ^a  

^a KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Dopamine agonist; Fibrosis; Parkinson's disease (PD); Valvular heart disease; Valvular regurgitation; Valvulopathy

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SEROTONIN 2B RECEPTOR;

AORTA VALVE REGURGITATION; ASIA; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FIBROSIS; HEART MUSCLE FIBROSIS; HEART VALVE REGURGITATION; HUMAN; LOW DRUG DOSE; MITRAL VALVE REGURGITATION; MONOTHERAPY; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; TREATMENT OUTCOME; TRICUSPID VALVE REGURGITATION; VALVULAR HEART DISEASE; WESTERN HEMISPHERE;

EID: 34548746965     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-007-5012-8     Document Type: Conference Paper

References (34)

1. Bana DS, MacNeal PS, Lecote PM, Shah Y, Graham JR (1974) Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. Am Heart J 88:640-655
2. Baseman DG, O'Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB Jr (2004) Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 63:301-304
3. Calne DB, Techynne PF, Claveria LE (1974) Bromocriptine in parkinsonism. Br J Med 4:442-444
4. Chung EJ, Yoon Wt, Kim J-Y, Lee WY (2006) Valvular heart disease in a patient with Parkinson's disease treated with a low daily dose and a low cumulative dose of pergolide. Mov Disord 21:586-587
5. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV (1997) Valvular heart disease associated with fenfluraminephentermine. N Engl J Med 337:581-588
6. Dhawan V, Medcalf P, Stegie F, Jackson G, Basu S, Luce P, Odin P, Ray Chaudhuri K (2005) Retrospective evaluation of cardio-pulmonary fibrosis side effects in symptomatic patients from a group of 234 Parkinson's disease patients treated with cabergoline. J Neural Transm 112:661-668
7. Flowers CM, Rascoosin JA, Lu SL, Beitz JG (2003) The US food and drug administration's registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 78:730-731
8. Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S, Raskoff WJ, Flachsbart KD, Rakowski H, Pache JC, Burkhard PR, Lang AE (2004) Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 19:656-662
9. Jahnichen S, Horowski R, Pertz HH (2005) Agonism at 5-HT2b receptor is not a class effect of the ergolines. Eur J Pharmacol 513:225-228
10. Junghanns S, Fuhrmann JT, Simonis G, Oelwein C, Koch R, Strasser RH, Reichmann H, Storch A (2007) Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study. Mov Disord 22:234-238
11. Kenangil G, Ozekemkci S, Koldas L, Sahin T, Erginoz E (2007) Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline. Clin Neurol Neurosurg 109:350-353
12. Kim J-Y, Vhung EJ, Park SW, Lee WY (2006) Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists. Mov Disord 21:1261-1264
13. Lang AE, Lozano AM (1988) Parkinson's disease (second part of two). N Engl J Med 229:1130-1143
14. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin J-A, Newman-Tancredi A (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and clones of human receptor subtypes. J Pharmacol Exp Ther 303:791-804
15. Mirapex® (premipexole dihydrochloride). Prescribing information (2006) Boehringer Ingelheim, USA, p 11
16. Muller T, Fritze J (2003) Fibrosis associated with dopamine agonist therapy in Parkinson's disease. Clin Neuropharmacol 26:109-111
17. Muraki M, Mikami T, Kitaguchi M, Sugawara T, Isonishi K, Kaneko S, Kashiwaba T, Moriwaka F, Yamada S, Onozuka H, Tsutsui H (2005) Effects of low-dose pergolide therapy on cardiac valves in patients with Parkinson's disease. J Cardiol 46:221-227
18. Peralta C, Wolf E, Alber H, Seppi K, Müller S, Bösch S, Wenning GK, Pachinger O, Poewe W (2006) Valvular heart disease in Parkinson's disease vs. control: an echocardiographic study. Mov Disord 21:1109-1113
19. Pinero A, Marcos-Alberta P, Fortes J (2005) Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med 353:18-19
20. Poewe W (2005) Drug therapy: dopamine agonists. In: Schapira AHV, Olanow CW (ed) Principles of Treatment in Parkinson's Disease. Butterworth-Heinemann Medical, Philadelphia, pp 25-47
21. Prichett AM, Morrison JF, Edwards W, Schaff HV, Connolly HM, Espinosa RE (2002) Valvular heart disease in patients taking pergolide. Mayo Clin Proc 77:1280-1286
22. Rascol O, Payoux P, Ory F Ferreira JJ, Brefel-Courbon C, Mantastruc JL (2003) Limitations of current Parkinson's disease therapy. Ann Neurol 53:S3-S12
23. Refield MM, Nicholson WJ, Edwards WD, Tajil AJ (1992) Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 117:50-52
24. ® Prescribing information (2006) GlaxoSmithKlein, USA, p 11
25. Robiolio PA, Rigolin VH, Wilson JS, Harrison JK, Sanders LL, Bashore TM, Feldman JM (1995) Carcinoid heart disease: correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 92:790-795
26. Schade R, Anderson F, Suissa S, Haverkamp W, Grabe E (2007) Dopamine agonist and the risk of cardiac-valve regurgitation. N Engl J Med 356:29-38
27. Scozzafava J, Takahashi J, Johnston W, Puttagunta L, Martin RWR (2006) Valvular heart disease in pergolide-treated Parkinson's disease. Can J Neurol Sci 33:111-113
28. Serratrice J, Disdier P, Habib G, Viallet F, Weiller P-J (2002) Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev 10:334-336
29. Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL (2003) 3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 63:1223-1229
30. Van Camp G, Flamez A, Cosyns B, Goldstein J, Perdaens C, Schoors D (2003) Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology 61:859-861
31. Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, De Sutter J, Santens P, Decoodt P, Moerman C, Schoors D (2004) Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 363:1179-1183
32. Waller EA, Kaplan J, Heckman M (2005) Valvular heart disease in patients taking pergolide. Mayo Clin Proc 80:1016-1020
33. Yamamoto M, Uesugi T, Nakayama T (2006) Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 67:1225-1229
34. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356:39-46